Europe opens up big new market for Roche's RA therapy RoActemra

Roche ($RHHBY) just won access to a larger market for its RoActemra treatment for rheumatoid arthritis. The Swiss drugmaker got the nod from European regulators to sell the drug to treat patients in the first two years after diagnosis. Report (sub. req.)